[go: up one dir, main page]

PE20090622A1 - Nuevos derivados de bencimidazol sustituido - Google Patents

Nuevos derivados de bencimidazol sustituido

Info

Publication number
PE20090622A1
PE20090622A1 PE2008001443A PE2008001443A PE20090622A1 PE 20090622 A1 PE20090622 A1 PE 20090622A1 PE 2008001443 A PE2008001443 A PE 2008001443A PE 2008001443 A PE2008001443 A PE 2008001443A PE 20090622 A1 PE20090622 A1 PE 20090622A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
lower alkyl
benzimidazole
phenoximethyl
benzoimidazol
Prior art date
Application number
PE2008001443A
Other languages
English (en)
Inventor
Gregory Martin Benson
Konrad Bleicher
Uwe Grether
Rainer E Martin
Hans Richter
Sven Taylor
Minmin Yang
Jean-Marc Plancher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090622A1 publication Critical patent/PE20090622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (I) DONDE X ES -O-, -S-, -S(O)-, -S(O)2-, ENTRE OTROS; R1 ES ALQUILO INFERIOR, CICLOALQUILO, CICLOALQUIL-ALQUILO INFERIOR, ENTRE OTROS; R2 ES H O ALQUILO INFERIOR; R3 ES CICLOALQUILO, CICLOALQUIL-ALQUILO INFERIOR, HETEROCICLILO, ENTRE OTROS; R4 ES ALQUILO INFERIOR, CICLOALQUILO, ARILO, ENTRE OTROS; R5, R6, R7 Y R8 SON CADA UNO H, HALOGENO, ALQUILO INFERIOR, ENTRE OTROS; R9 Y R10 SON CADA UNO H, ALQUILO INFERIOR, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(4-CLORO-2-METIL-FENOXIMETIL)-6-FLUOR-BENZOIMIDAZOL-1-IL]-2,N-DICICLOHEXIL-ACETAMIDA, 2,N-DICICLOHEXIL-2-[6-FLUOR-2-(4-HIDROXIMETIL-FENOXIMETIL)-BENZOIMIDAZOL-1-IL]-ACETAMIDA, 2-[2-(4-CLORO-FENOXIMETIL)-6-FLUOR-BENZOIMIDAZOL-1-IL]-2,N-DICICLOHEXIL-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR X DE FARNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE DISLIPIDEMIAS, ENFERMEDAD ATEROSCLEROTICA, SINDROME METABOLICO
PE2008001443A 2007-08-27 2008-08-26 Nuevos derivados de bencimidazol sustituido PE20090622A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07115005 2007-08-27

Publications (1)

Publication Number Publication Date
PE20090622A1 true PE20090622A1 (es) 2009-05-16

Family

ID=39967744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001443A PE20090622A1 (es) 2007-08-27 2008-08-26 Nuevos derivados de bencimidazol sustituido

Country Status (15)

Country Link
US (1) US7790904B2 (es)
EP (1) EP2188263B1 (es)
JP (1) JP5204232B2 (es)
KR (1) KR101237577B1 (es)
CN (1) CN102083799B (es)
AR (1) AR070648A1 (es)
AU (1) AU2008291148B2 (es)
BR (1) BRPI0815696A2 (es)
CA (1) CA2697167C (es)
CL (1) CL2008002506A1 (es)
ES (1) ES2387230T3 (es)
MX (1) MX2010002341A (es)
PE (1) PE20090622A1 (es)
TW (1) TW200916099A (es)
WO (1) WO2009027264A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818813A2 (pt) * 2007-11-15 2015-04-22 Hoffmann La Roche Compostos derivados de metil-benzimidazol, processo para a manufatura desses compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ ou profilático de enfermidades que são afetadas por moduladores de fxr e uso de tais compostos
WO2010028981A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag New benzimidazole derivatives
US8309581B2 (en) * 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
LT3043865T (lt) 2013-09-11 2021-04-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Hepatito b viruso infekcijos gydymo būdai ir farmacinė kompozicija
CN106632065B (zh) * 2016-12-06 2019-08-30 沈阳药科大学 苯并咪唑类化合物及其应用
CN106905241B (zh) * 2017-02-14 2020-03-17 沈阳药科大学 1,2-二取代苯并咪唑衍生物及其应用
CA3051776A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar and fxr agonist for the treatment of liver disorders
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
CA3159163A1 (en) 2020-01-15 2021-07-22 Raphael Darteil Use of fxr agonists for treating an infection by hepatitis d virus
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
US20240216364A1 (en) 2021-04-28 2024-07-04 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
JP4656838B2 (ja) * 2002-02-06 2011-03-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
CA2530081A1 (en) * 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
RU2424233C2 (ru) 2006-06-29 2011-07-20 Ф.Хоффманн-Ля Рош Аг Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты

Also Published As

Publication number Publication date
CL2008002506A1 (es) 2009-06-12
JP2010536915A (ja) 2010-12-02
AU2008291148A1 (en) 2009-03-05
TW200916099A (en) 2009-04-16
BRPI0815696A2 (pt) 2016-06-21
CN102083799B (zh) 2013-10-16
AR070648A1 (es) 2010-04-28
JP5204232B2 (ja) 2013-06-05
AU2008291148B2 (en) 2011-03-17
KR101237577B1 (ko) 2013-02-26
ES2387230T3 (es) 2012-09-18
CN102083799A (zh) 2011-06-01
EP2188263B1 (en) 2012-06-27
MX2010002341A (es) 2010-03-22
US7790904B2 (en) 2010-09-07
CA2697167A1 (en) 2009-03-05
CA2697167C (en) 2013-07-16
EP2188263A1 (en) 2010-05-26
WO2009027264A1 (en) 2009-03-05
KR20100051734A (ko) 2010-05-17
US20090062356A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20141375A1 (es) Activadores de glucoquinasa
PE20080278A1 (es) Compuestos de benzimidazolilo
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20090999A1 (es) Nuevos derivados de metil-bencimidazol
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20110703A1 (es) Acidos naftilaceticos
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20110574A1 (es) Derivados de fenilamida y de piridilamida como agonistas de gpbar1
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
PE20091694A1 (es) DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal